Life Extension Final Clerance Sale

Life Extension Suggestions

Follow your physician's recommendations concerning the addition of daily dietary supplements. Multivitamins, minerals, and other supplements may be prescribed or recommended to help replace essential nutrients lost during dialysis treatments. Consult medical professionals experienced in treating kidney disorders and follow their treatment recommendations carefully. Establish appropriate dietary habits. The following supplements are supportive of overall kidney health. The recommendations are for healthy individuals. If you have any form of kidney disease, consult your physician before adding or changing any supplements you may currently be taking.

In addition, the following blood tests may provide helpful information.

Overlooked Prescription Drug Kidneys are especially vulnerable to attack by proinflammatory cytokines. Pentoxifylline (PTX) is a drug that has been shown to protect against this type of kidney damage. The suggested dose of PTX is 400 mg twice daily.

PTX should not be used in patients with bleeding disorders such as those with recent cerebral or retinal hemorrhage. Patients taking Coumadin should have more frequently monitored prothrombin time. Those suffering from other types of bleeding should receive frequent physician examinations. Furthermore, consider having a physician evaluate coagulation status to see what effect PTX has on template bleeding time. This is an inexpensive test that relates to the biological effect of PTX or other agents like aspirin (non-steroidal anti-inflammatory agents) on platelet function. All of these agents affect platelet aggregation and this effect can be manifested in a prolonged template bleeding time. According to two studies, PTX should be avoided by Parkinson's patients. It is important to note that the body does use TNF-α to acutely fight infection(s). If patients are showing any sign of infectious disease, drugs like Enbrel® that inhibit the effects of TNF-α are temporarily discontinued. A new FDA advisory states that patients should be tested and treated for inactive, or latent tuberculosis prior to therapy with another TNF-α inhibiting therapy (eg, infliximab). Since PTX, fish oil, and nettle directly suppress TNF-α, perhaps these agents should be temporarily discontinued during the time when one has an active infection.